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ABSTRACT Recombinant Candida albicans CYP51 (CaCYP51) proteins containing 23
single and 5 double amino acid substitutions found in clinical strains and the wild-
type enzyme were expressed in Escherichia coli and puriﬁed by Ni2-nitrilotriacetic
acid agarose chromatography. Catalytic tolerance to azole antifungals was assessed
by determination of the concentration causing 50% enzyme inhibition (IC50) using
CYP51 reconstitution assays. The greatest increase in the IC50 compared to that
of the wild-type enzyme was observed with the ﬁve double substitutions
Y132FK143R (15.3-fold), Y132HK143R (22.1-fold), Y132FF145L (10.1-fold),
G307SG450E (13-fold), and D278NG464S (3.3-fold). The single substitutions
K143R, D278N, S279F, S405F, G448E, and G450E conferred at least 2-fold in-
creases in the ﬂuconazole IC50, and the Y132F, F145L, Y257H, Y447H, V456I,
G464S, R467K, and I471T substitutions conferred increased residual CYP51 activity
at high ﬂuconazole concentrations. In vitro testing of select CaCYP51 mutations in C.
albicans showed that the Y132F, Y132H, K143R, F145L, S405F, G448E, G450E, G464S,
Y132FK143R, Y132FF145L, and D278NG464S substitutions conferred at least a
2-fold increase in the ﬂuconazole MIC. The catalytic tolerance of the puriﬁed pro-
teins to voriconazole, itraconazole, and posaconazole was far lower and limited to
increased residual activities at high triazole concentrations for certain mutations
rather than large increases in IC50 values. Itraconazole was the most effective at in-
hibiting CaCYP51. However, when tested against CaCYP51 mutant strains, posacona-
zole seemed to be the most resistant to changes in MIC as a result of CYP51 muta-
tion compared to itraconazole, voriconazole, or ﬂuconazole.
KEYWORDS Candida albicans CYP51, azole, mutations
Candida albicans causes a wide range of clinical infections in humans, rangingfrom mucosal infections, such as oral candidiasis and thrush, to potentially life-
threatening systemic candidemia and candidiasis. The incidence of fungal infections
caused by C. albicans and non-albicans Candida species has steadily increased over the
last 2 decades in part due to HIV-AIDS but also as a result of the growing number of
patients who are immunodeﬁcient through organ and bone marrow transplants and
cancer treatments (1). Candida bloodstream infections cause signiﬁcant mortality and
morbidity, particularly among intensive care patients (2, 3). Predisposing factors for
invasive candidiasis include cytotoxic and immunosuppressive therapies, HIV-AIDS,
treatment with broad-spectrum antibiotics, diabetes, and in situ urinary tract and
central venous catheters (4–6). Controlling invasive fungal infections among oncology,
hematology, and intensive care patients is a growing concern (7).
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Azole antifungals are relatively safe, have a high therapeutic index, and are easy to
administer (often by mouth), leading to the adoption of triazole antifungals as the
standard ﬁrst-line therapy against fungal infections. However, prolonged treatment
regimens in the clinic and the prophylactic use of azole drugs have led to an increasing
incidence of azole-resistant Candida strains. Four molecular mechanisms have been
demonstrated to confer azole resistance in Candida (8, 9). These include overexpression
of efﬂux transporters (C. albicans Cdr1 [CaCdr1], CaCdr2, and CaMdr1) (10, 11), point
mutations that alter the amino acid sequence of CYP51 (ERG11) (12–14), overexpression
of CYP51, and alterations in the ergosterol biosynthetic pathway, such as mutations in
ERG3. These resistance mechanisms are often combined in clinical isolates (15–20).
More than 140 different amino acid substitution mutations have been reported in
the C. albicans CYP51 (CaCYP51) gene from clinical strains, although not all substitu-
tions confer an azole resistance phenotype (13, 14, 21–23). The CYP51 genes of both
azole-susceptible and azole-resistant clinical isolates may contain several amino acid
substitutions. The majority of these mutations cluster into three hot spots, located
within residues 105 to 165, 266 to 287, and 405 to 488 (21). Not all amino acid
substitutions contribute equally to azole resistance, with K143R, S405F, G464S, R467K,
and I471T being present only in CYP51 genes recovered from azole-resistant strains,
whereas E266D, V437I, and V488I have been found in CYP51 genes from both azole-
susceptible and azole-resistant strains, suggesting that the last three substitutions do
not confer azole resistance (23). CYP51-mediated azole resistance has been investigated
further through genetic manipulation by introducing CYP51 genes on plasmids into a
model Saccharomyces cerevisiae system and then assessing azole sensitivity (14, 24, 25).
In addition, several CaCYP51 constructs of the enzyme catalytic domain containing
amino acid substitutions, including Y132H, F145L, I471T, and S279F, have been ex-
pressed in Escherichia coli, puriﬁed, and characterized (26–29).
In this study, we report the expression in E. coli, isolation, and puriﬁcation of
recombinant CaCYP51 proteins that were modiﬁed at the N terminus and His tagged
at the C terminus and that had 1 of 23 single amino acid substitutions or 5 double
amino acid substitutions. The effects of the amino acid substitutions were assessed in
terms of catalytic turnover and sensitivity to inhibition by ﬂuconazole, itraconazole,
voriconazole, and posaconazole using CYP51 reconstitution assays and azole ligand
binding studies. The effects of selected single and double amino acid substitutions in
CaCYP51 proteins on susceptibility were further tested in vitro by introducing mutant
alleles of the CYP51 gene into an azole-susceptible C. albicans strain. The aim of this
study was to establish which CaCYP51 amino acid substitutions conferred biochemical
azole tolerance to the CYP51 catalytic function and their impact on in vitro azole
susceptibility.
RESULTS
Puriﬁcation and enzyme catalysis of CaCYP51 proteins. The yield of the CaCYP51
proteins after puriﬁcation on Ni2-nitrilotriacetic acid (NTA) agarose varied from 32
nmol per liter of culture (I471T) to 235 nmol per liter (F126V) (Table 1), indicating a
7-fold variability in expression levels in E. coli between recombinant CaCYP51 proteins.
The same expression and cell breakage/solubilization conditions were used for all the
CaCYP51 proteins. The CaCYP51 amino acid substitutions that gave low yields of native
protein gave cell debris pellets after ultracentrifugation that were notably more red-
brown in color than the pellets of the wild-type expression clone, suggesting the
increased occurrence of inclusion bodies. Optimization of the expression and solubili-
zation conditions for each CaCYP51 protein should increase native protein yields. The
absolute absorbance spectra of all the CaCYP51 proteins were similar (Fig. 1; see also
Fig. S1 in the supplemental material) with , , Soret (), and  spectral bands at 566,
536, 418, and 360 nm, respectively, indicative of low-spin ferric cytochrome P450
enzymes (30, 31). Variability in the Soret peak between the CaCYP51 proteins was only
1 nm. Dithionite-reduced carbon monoxide difference spectra for all the CaCYP51
proteins yielded a characteristic red-shifted heme Soret peak at 448 nm (Fig. S2),
Warrilow et al. Antimicrobial Agents and Chemotherapy
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indicating that the CYP51 proteins were isolated in their native form. The main
difference between the CaCYP51 proteins was the rate at which the heme Soret peak
at 448 nm formed. There appeared to be little inactivated CaCYP51 (indicated by the
appearance of a heme Soret peak at420 nm for P420) present in the puriﬁed proteins.
For K143R, approximately 15% of the native form of the protein was converted to the
TABLE 1 Yield and relative velocities of CaCYP51 proteins
CaCYP51 substitution Yielda (nmol liter1) Relative velocityb
Wild type 119 1.000 0.047
Y118A 49 0.029 0.001
F126V 235 0.298 0.008
Y132F 53 0.795 0.005
Y132H 28 0.135 0.002
K143R 143 0.599 0.010
F145L 35 0.476 0.021
P230L 71 0.250 0.003
Y257H 93 0.554 0.029
D278N 177 0.645 0.028
S279F 152 0.289 0.017
G307S 193 0.031 0.001
S405F 66 0.758 0.011
V437I 37 0.796 0.013
Y447H 36 0.965 0.019
G448E 35 0.407 0.007
F449Y 44 0.548 0.088
G450E 163 0.517 0.019
V456I 157 1.560 0.018
G464S 29 0.609 0.023
R467K 38 0.471 0.023
I471T 32 0.634 0.015
Q474K 35 1.601 0.035
V488I 152 1.167 0.032
Y132FK143R 67 0.208 0.014
Y132HK143R 79 0.068 0.001
Y132FF145L 93 0.405 0.012
D278NG464S 48 0.327 0.002
G307SG450E 136 0.077 0.008
aThe yield of puriﬁed CaCYP51 protein isolated from 1 liter of E. coli expression culture.
bA relative velocity of 1.000 relates to a catalytic turnover number of 0.574 min1 obtained with the wild-
type CaCYP51 protein in the CYP51 reconstitution assay.
FIG 1 Absolute spectra of the wild-type CaCYP51 protein and CaCYP51 proteins with double amino acid
substitutions. The puriﬁed CaCYP51 proteins were diluted 20-fold with 0.1 M Tris-HCl buffer (pH 8.1) and
20% glycerol, and the absolute spectra in the resting oxidized state were determined between 300
and 700 nm. The absolute spectra for the CaCYP51 proteins with single amino acid substitutions can be
found in Fig. S1 in the supplemental material.
C. albicans CYP51 Amino Acid Substitutions Antimicrobial Agents and Chemotherapy
May 2019 Volume 63 Issue 5 e02586-18 aac.asm.org 3
 o
n
 M
ay 8, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
P420 inactive form after 6 min, suggesting instability in the presence of sodium
dithionite.
Catalytic turnover assayed by using lanosterol as the substrate and in the presence
of a cognate human cytochrome P450 reductase (HsCPR) varied between puriﬁed
CaCYP51 proteins (Table 1), with the highest turnover numbers of 0.896 and
0.919 min1 being observed with the V456I and Q474K proteins, respectively. In
contrast, the G307SG450E, Y132HK143R, G307S, and Y118A proteins had the lowest
catalytic turnover numbers of 0.044, 0.039, 0.018, and 0.016 min1, respectively,
whereas the value was 0.574 min1 for wild-type CaCYP51, using HsCPR as the redox
partner. Most (20/23) enzymes with CaCYP51 single amino acid substitutions and all
enzymes with double substitutions were catalytically less efﬁcient than the wild-type
enzyme (Table 1).
Azole IC50 studies. Several CaCYP51 amino acid substitutions conferred tolerance
to inhibition of in vitro CYP51 activity by ﬂuconazole (Table 2). Among the single
substitutions, K143R, S279F, and G450E appeared to confer the greatest catalytic
tolerance to inhibition by ﬂuconazole (Fig. 2, 3, and 4), yielding values of the concen-
tration causing 50% enzyme inhibition (IC50) 3-fold higher than the IC50 for the
wild-type enzyme. The D278N, S405F, and G448E enzymes gave ﬂuconazole IC50 values
2-fold higher than the IC50 for the wild-type enzyme. In addition, signiﬁcant residual
CYP51 activities (3% to 28%) were observed in the presence of 4 M ﬂuconazole for the
enzymes with the Y132F, K143R, F145L, Y257H, D278N, S279F, S405F, Y447H, G448E,
G450E, V456I, G464S, R467K, and I471T substitutions (Table 3; Fig. S4), suggesting that
these substitutions confer catalytic tolerance to ﬂuconazole. The double substitutions
conferred the greatest catalytic tolerance to ﬂuconazole in vitro compared to the IC50
for the wild-type enzyme, with 3-, 10-, 13-, 15-, and 22-fold increased IC50 values
TABLE 2 Triazole antifungal IC50 values obtained with CaCYP51 proteins
CaCYP51 substitution
IC50a (M)
Fluconazole Voriconazole Itraconazole Posaconazole
Wild type 0.384 0.019 0.197 0.009 0.389 0.013 0.195 0.009
Y118A 0.194 0.010 0.202 0.002 0.170 0.016 0.206 0.004
F126V 0.278 0.027 0.341 0.020 0.206 0.009 0.304 0.070
Y132F 0.606 0.066 0.429 0.012 0.309 0.003 0.343 0.020
Y132H 0.220 0.013 0.197 0.029 0.150 0.028 0.195 0.003
K143R 1.100 0.313 0.424 0.035 0.450 0.016 0.789 0.003
F145L 0.450 0.083 0.231 0.031 0.300 0.013 0.359 0.018
P230L 0.334 0.086 0.241 0.042 0.265 0.038 0.238 0.002
Y257H 0.512 0.047 0.350 0.039 0.336 0.014 0.611 0.017
D278N 0.838 0.027 0.555 0.004 0.545 0.044 0.908 0.020
S279F 1.046 0.325 0.487 0.002 0.569 0.121 0.912 0.016
G307S 0.526 0.211 0.439 0.018 0.225 0.007 0.288 0.042
S405F 0.820 0.042 0.362 0.086 0.350 0.019 0.637 0.054
V437I 0.281 0.004 0.304 0.002 0.293 0.022 0.319 0.009
Y447H 0.483 0.018 0.377 0.055 0.299 0.039 0.439 0.135
G448E 0.796 0.087 0.339 0.011 0.238 0.013 0.542 0.051
F449Y 0.245 0.028 0.361 0.010 0.222 0.011 0.366 0.037
G450E 1.078 0.247 0.427 0.031 0.458 0.070 0.908 0.132
V456I 0.483 0.022 0.469 0.023 0.603 0.002 0.602 0.017
G464S 0.455 0.047 0.278 0.038 0.282 0.006 0.253 0.024
R467K 0.476 0.080 0.298 0.049 0.235 0.018 0.380 0.011
I471T 0.600 0.017 0.318 0.015 0.218 0.002 0.522 0.064
Q474K 0.358 0.008 0.325 0.002 0.246 0.006 0.301 0.017
V488I 0.520 0.057 0.457 0.016 0.449 0.016 0.481 0.052
Y132FK143R 5.857 0.524 0.580 0.099 0.190 0.002 0.246 0.024
Y132HK143R 8.471 1.271 3.074 0.042 0.237 0.007 0.196 0.007
Y132FF145L 3.889 0.077 1.158 0.231 0.364 0.023 0.433 0.102
D278NG464S 1.243 0.064 0.552 0.045 0.403 0.011 0.930 0.009
G307SG450E 4.980 0.054 0.433 0.033 0.318 0.017 0.312 0.015
aIC50 determinations were performed in duplicate. Mean IC50 values together with standard deviations are
shown. Bold values indicate IC50 values that are over 2-fold greater than those obtained with the wild-type
protein.
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for ﬂuconazole (Table 2) being observed with the D278NG464S, Y132FF145L,
G307SG450E, Y132FK143R, and Y132HK143R enzymes, respectively. This was also
reﬂected in the high residual CYP51 activities of 18% to 75% observed with the double
substitution CaCYP51 enzymes in the presence of 4 M ﬂuconazole (Table 3; Fig. S4).
The IC50 experiments indicated that nine single substitutions (Y118A, F126V, Y132H,
P230L, G307S, V437I, F449Y, Q474K, and V488I) appeared to confer no increase in
catalytic tolerance to ﬂuconazole. The ineffectiveness of the V437I and V488I proteins
was expected, as these substitutions occur in both azole-sensitive and azole-resistant C.
albicans strains (23).
Based on the IC50 values (Table 2), catalytic tolerance to voriconazole was less
pronounced than that to ﬂuconazole among the CaCYP51 proteins, with only 2- to
3-fold increases in IC50s being observed with the Y132F, K143R, D278N, S279F, G307S,
G450E, V456I, Y132FK143R, D278NG464S, and G307SG450E enzymes. The great-
est tolerance to voriconazole was observed with the Y132FF145L and Y132HK143R
enzymes, which gave IC50 values 6- and 16-fold higher than the IC50 observed for the
wild-type CaCYP51 enzyme. In addition, residual CYP51 activities of over 3% were
observed with the K143R, S279F, G450E, Y132FK143R, Y132HK143R, Y132FF145L,
and D278NG464S enzymes in the presence of 4 M voriconazole (Table 3; Fig. S4),
relative to 0.11% residual activity for the wild-type enzyme.
The IC50 values obtained for itraconazole with the CaCYP51 proteins with amino acid
substitutions ranged from 0.15 and 0.60 M (Table 2), whereas the IC50 for the
wild-type enzyme was 0.39 M. However, residual CYP51 activities of 3% to 8% in the
presence of 4 M itraconazole (Table 3; Fig. S4) indicate limited catalytic tolerance to
FIG 2 Triazole IC50 determinations for wild-type CaCYP51 and CaCYP51 proteins containing Y132F,
Y132H, K143R, and F145L amino acid substitutions. IC50 values were determined for ﬂuconazole (ﬁlled
circles), voriconazole (hollow circles), itraconazole (ﬁlled triangles), and posaconazole (crosses). IC50
assays were performed in duplicate. Mean data points together with standard deviations (as error bars)
are shown.
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itraconazole due to the K143R, D278N, S279F, G450E, V456I, and D278NG464S
substitutions.
The IC50 values obtained for posaconazole varied between 0.2 M (for the wild-type
enzyme) and 0.93 M (for the D278NG464S enzyme) (Table 2), suggesting poor
catalytic tolerance to posaconazole among the CaCYP51 proteins. Residual CYP51
FIG 3 Triazole IC50 determinations for CaCYP51 proteins containing D278N, G307S, G450E, and G464S
amino acid substitutions. IC50 values were determined for ﬂuconazole (ﬁlled circles), voriconazole (hollow
circles), itraconazole (ﬁlled triangles), and posaconazole (crosses). IC50 assays were performed in dupli-
cate. Mean data points together with standard deviations (as error bars) are shown.
FIG 4 Triazole IC50 determinations for CaCYP51 proteins containing S279F, S405F, Y447H, G448E, R467K,
and I471T amino acid substitutions. IC50 values were determined for ﬂuconazole (ﬁlled circles), voricona-
zole (hollow circles), itraconazole (ﬁlled triangles), and posaconazole (crosses). IC50 assays were per-
formed in duplicate. Mean data points together with standard deviations (as error bars) are shown.
Warrilow et al. Antimicrobial Agents and Chemotherapy
May 2019 Volume 63 Issue 5 e02586-18 aac.asm.org 6
 o
n
 M
ay 8, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
activities of 3% to 21% in the presence of 4 M posaconazole (Table 3; Fig. S4)
conﬁrmed the limited catalytic tolerance to posaconazole for the enzymes with the
K143R, Y257H, D278N, S279F, S405F, Y447H, G448E, F449Y, G450E, V456I, R467K, I471T,
Q474K, and D278NG464S substitutions. P230L, previously predicted to confer itra-
conazole and posaconazole resistance (32, 33), did not confer catalytic tolerance to
either itraconazole or posaconazole using in vitro CaCYP51 reconstitution assays.
Azole ligand binding. Fluconazole, voriconazole, itraconazole, and posaconazole
bound to all CaCYP51 proteins, producing type II difference spectra indicative of the
triazole ring N-4 nitrogen coordinating as the sixth ligand with the heme iron (34) to
form the low-spin CYP51-azole complex, resulting in a red shift of the heme Soret peak.
The ﬂuconazole binding difference spectra obtained with the CaCYP51 proteins with
double substitutions identiﬁed a number of differences from the wild-type protein (Fig.
5). Both the D278NG464S and G307SG450E proteins gave type II difference spectra
that were similar to the spectrum of the wild-type CaCYP51 protein with peaks at
428 to 430 nm and troughs at 412 nm. However, both the Y132FK143R and
Y132HK143R proteins gave less intense difference spectra (change in absorbance
[ΔA]), with a blue-shifted peak at 421 nm and a blue-shifted trough at 367 to 371 nm.
Likewise, the Y132FF145L protein gave a less intense blue-shifted spectrum, with a
peak at 423 nm and a broad trough extending from 371 to 411 nm relative to the
wild-type protein. These relatively weak blue-shifted type II difference spectra (ΔA)
suggest that the Fe-N coordination between the triazole N-4 atom and the heme ferric
ion has been weakened (35) because either the orientation of the triazole moiety is
unfavorable or the length of the Fe-N bond has been increased. The ﬂuconazole
binding difference spectra of the enzymes with the single substitutions Y132F, Y132H,
K143R, and F145L (Fig. S3) were all type II difference spectra, albeit with slightly
TABLE 3 Residual CYP51 activity in the presence of 4 M triazole antifungal
CaCYP51 substitution
Residual CYP51 activity (%)  SDa
Fluconazole Voriconazole Itraconazole Posaconazole
Wild type 0.11 0.09 0.11 0.01 0.03 0.02 0.66 0.02
Y118A 1.510.01 0.28 0.04 1.30 0.59 0.46 0.35
F126V 0.09 0.06 0.19 0.06 0.22 0.05 0.10 0.01
Y132F 7.05 0.27 1.09 0.05 0.19 0.04 0.930.01
Y132H 0.86 0.07 0.33 0.19 0.070.01 0.18 0.06
K143R 28.14 2.04 3.12 0.27 6.27 0.51 13.09 0.02
F145L 6.71 0.15 0.37 0.11 1.99 0.04 1.37 1.21
P230L 0.05 0.03 0.13 0.12 0.06 0.01 0.21 0.05
Y257H 3.96 0.18 0.63 0.27 1.37 0.28 6.42 0.59
D278N 7.59 0.58 1.34 0.05 3.00 0.19 14.82 0.92
S279F 17.99 1.67 6.15 0.66 5.97 0.35 20.64 0.10
G307S 0.95 0.17 0.41 0.04 0.53 0.21 0.71 0.04
S405F 11.56 1.41 1.94 0.12 2.73 0.13 9.38 0.53
V437I 0.22 0.06 0.020.01 0.13 0.02 0.59 0.20
Y447H 4.34 0.51 2.07 1.04 1.45 0.06 8.19 3.58
G448E 10.46 0.20 1.89 0.61 1.75 0.26 7.89 0.29
F449Y 0.76 0.08 0.56 0.12 0.84 0.57 5.42 0.04
G450E 18.93 0.94 3.50 0.17 7.66 0.54 15.57 0.21
V456I 3.68 0.95 0.79 0.07 3.21 0.07 6.66 0.05
G464S 3.05 0.17 0.10 0.01 0.54 0.11 0.54 0.09
R467K 3.34 0.61 0.52 0.18 0.45 0.17 3.62 0.09
I471T 4.35 0.33 0.92 0.05 1.21 0.01 7.71 0.58
Q474K 0.71 0.08 0.34 0.04 0.49 0.04 3.23 0.18
V488I 1.06 0.04 0.13 0.08 0.980.01 2.11 0.14
Y132FK143R 62.04 1.21 8.86 1.09 0.23 0.13 0.86 0.11
Y132HK143R 68.81 5.68 39.59 8.63 0.70 0.03 0.74 0.05
Y132FF145L 49.10 1.76 13.58 0.19 0.91 0.05 2.64 0.08
D278NG464S 18.26 0.08 4.79 0.11 3.19 0.46 14.97 1.16
G307SG450E 56.75 2.30 0.41 0.10 0.20 0.04 0.26 0.11
aResidual activity is expressed as a percentage of the CYP51 activity observed in the absence of triazole
antifungals. Each assay was performed in duplicate. These data are also represented graphically in Fig. S4 in
the supplemental material. Residual CYP51 activities greater than 3% are indicated in bold.
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blue-shifted peak maxima at 425 to 427 nm compared to the spectrum of the wild-type
protein (429 nm). Therefore, the altered ﬂuconazole difference spectra observed with
the Y132FK143R, Y132HK143R, and Y132FF145L enzymes appeared to be a
cumulative effect rather than an effect attributable to one particular amino acid
substitution.
Ligand binding studies with ﬂuconazole gave dissociation constant (Kd) values
ranging from 7 to 90 nM for all CaCYP51 proteins with single amino acid substitutions,
except for K143R (Kd, 118 24 [standard deviation] nM), D278N (Kd, 120 35 nM),
G307S (Kd, 133 13 nM), and S279F (Kd, 232 36 nM). The double substitutions
D278NG464S, G307SG450E, Y132FF145L, Y132FK143R, and Y132HK143R
gave Kd values for ﬂuconazole of 15 9, 158 38, 202 57, 15,600 3,900, and
18,100 4,800 nM, respectively. The ligand binding studies accurately predicted the
ﬂuconazole tolerance conferred by the double substitutions Y132FK143R and
Y132HK143R but not the catalytic tolerance to ﬂuconazole conferred by
Y132FF145L, G307SG450E, D278NG464S, K143R, D278N, S279F, S405F, G448E,
and G450E in the IC50 studies.
Preliminary ligand binding studies with voriconazole and the CaCYP51 proteins gave
Kd values ranging from 3 to 100 nM, with only the Y132FK143R and Y132HK143R
enzymes having substantially higher Kd values of 2,300 310 and 8,000 1,200 nM,
respectively. Similarly, ligand binding studies for the CaCYP51 proteins with itracona-
zole and posaconazole gave Kd values ranging from 1 to 70 nM, with the exception
of those for enzymes with Y132FK143R (Kd for itraconazole, 127 33 nM) and
Y132HK143R (Kd for itraconazole, 387 117 nM; Kd for posaconazole, 162 59 nM).
Direct ligand binding studies with voriconazole, itraconazole, and posaconazole did not
FIG 5 Fluconazole binding properties of CaCYP51 proteins. Type II difference spectra for 4 M wild-type
CaCYP51 and the ﬁve CaCYP51 proteins with double substitutions are shown along with the ligand
binding saturation curves for the wild-type protein (ﬁlled circles) and proteins with the Y132FK143R
(hollow circles), Y132HK143R (ﬁlled triangles), Y132FF145L (crosses), D278NG464S (hollow trian-
gles), and G307SG450E (hollow squares) substitutions. Ligand binding determinations were performed
in triplicate, although only one replicate is shown. Ligand saturation curves were ﬁtted using the
modiﬁed Morrison equation (54).
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predict the observed catalytic tolerance to these three azoles conferred by several
CaCYP51 amino acid substitutions in the IC50 experiments, as evident by the residual
activities in the presence of 4 M triazole antifungal (Table 3; Fig. S4).
In vitro assessment of CaCYP51 substitutions in C. albicans. In order to deter-
mine the impact of CYP51 amino acid substitutions on in vitro azole susceptibility in C.
albicans, we selected several mutations representative of those that led to the greatest
biochemical effect on the CYP51 enzyme. When mutant alleles were introduced into
the ﬂuconazole-susceptible parent strain SC5314, CaCYP51 amino acid substitutions
displayed variable effects on the azole drug MIC (Table 4). The effects of nine single
CYP51 amino acid substitutions and three double CYP51 amino acid substitutions on
the ﬂuconazole, voriconazole, itraconazole, and posaconazole MICs were tested. The
G450E and K143R amino acid substitutions produced the greatest relative increase in
the MIC of ﬂuconazole, with each producing a 16-fold increase in the MIC compared to
that for the reference strain, SC5314, which lacks any substitution in CYP51. The strains
containing the CYP51 single amino acid substitutions Y132F, G448E, and G464S also
demonstrated resistance to ﬂuconazole, displaying an 8-fold increase in MIC over that
for SC5314. The overall strongest effect on the ﬂuconazole MIC occurred with the
double substitutions Y132FK143R and Y132FF145L, each conferring a 32-fold in-
crease in the ﬂuconazole MIC. Against voriconazole, the single substitutions Y132F,
K143R, F145L, and G450E had the greatest effect on the MIC, and the strongest in vitro
effect was observed with the Y132FK143R and Y132FF145L double substitutions.
When tested against itraconazole, most of the strains with a CYP51 substitution showed
a small increase in MIC, with the strain with the strongest single amino acid substitu-
tion, K143R, displaying an MIC (0.5 g ml1) greater than that for any of the strains with
the double amino acid substitutions. In contrast to the other azoles, posaconazole
appeared to be very effective against all CYP51 mutant strains, as the MICs for the
reference strain and all other strains tested were identical, with the exception of the
strain containing the single G448E substitution, which displayed a slight 2-fold increase
in MIC over that for SC5314.
DISCUSSION
Previous investigations identiﬁed all the CaCYP51 mutations studied here, with the
exception of V437I and V488I, as conferring azole resistance (13, 14, 21–23). While the
isolated contributions of endogenously expressed CYP51 gene mutations to azole
resistance have been studied in C. albicans individually (36), here we compared
the azole-CYP51 binding interactions and enzyme activity of recombinant CYP51
proteins with amino acid substitutions in conjunction with the effects of those changes
on azole susceptibility in C. albicans.
TABLE 4 CLSI MICs of ﬂuconazole, voriconazole, itraconazole, and posaconazole for
strains containing CYP51 amino acid substitutions
CaCYP51 substitution
MIC (g ml1)
Fluconazole Voriconazole Itraconazole Posaconazole
Nonea 1 0.03 0.06 0.03
Y132F 8 0.5 0.25 0.03
Y132H 2 0.25 0.25 0.03
K143R 16 0.5 0.5 0.03
F145L 4 0.5 0.25 0.03
D278N 1 0.03 0.125 0.03
S405F 4 0.25 0.25 0.03
G448E 8 0.25 0.25 0.06
G450E 16 0.5 0.25 0.03
G464S 8 0.25 0.25 0.03
Y132FK143R 32 1 0.25 0.03
Y132FF145L 32 1 0.25 0.03
D278NG464S 8 0.25 0.25 0.03
aFluconazole-susceptible parent strain SC5314.
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Amino acid substitutions associated with an increase in azole tolerance are often at
the expense of a reduction in catalytic efﬁciency, as has been seen previously (26, 37,
38). In this study, the catalytic rate varied 56-fold between the CYP51 proteins using
lanosterol as the substrate and HsCPR as the redox partner. The lowest rate was seen
with the Y118A mutant enzyme (0.0164 min1), and the highest was seen with the
Q474K mutant enzyme (0.919 min1), whereas a rate of 0.574 min1 was observed with
the wild-type enzyme. Only enzymes with the V456I, Q474K, and V488I substitutions
gave catalytic rates greater than the rate for the wild-type enzyme (Table 1). These
higher base relative velocities of the uninhibited CYP51 variants may partly explain the
elevated MICs observed previously in some clinical C. albicans isolates.
Our IC50 studies showed that of the 23 single amino acid substitutions tested, only
6 (K143R, D278N, S279F, S405F, G448E, G450E) caused 2-fold or greater increases in the
observed IC50 values for ﬂuconazole (Table 2). Similarly, with voriconazole and po-
saconazole, greater than 2-fold increases in the IC50 were observed for 7 single
substitutions (Y132F, K143R, D278N, S279F, G450E, V456I, and V488I) and 11 single
amino acid substitutions (K143R, Y257H, D278N, S279F, S405F, Y447H, G448E, G450E,
V456I, I471T, and V488I), respectively (Table 2). This was in contrast to the ﬁndings for
itraconazole, where none of the substituted CaCYP51 proteins gave IC50 values greater
than 1.6-fold that of the wild-type enzyme.
The double substitutions yielded larger increases in the observed IC50 values for
both ﬂuconazole and voriconazole. These increases ranged from 3.2-fold for
D278NG464S to 22-fold for Y132HK143R with ﬂuconazole and from 2-fold
for G307SG450E to 15.6-fold for Y132HK143R with voriconazole, indicating a re-
duced afﬁnity for ﬂuconazole and voriconazole. These observations are consistent with
the CaCYP51 structure (39), in which residues Y132, K143, G307, and S405 are exposed
in the active-site cavity and substitution at these residue positions is likely to cause
altered ﬂuconazole and voriconazole binding. An increase in the IC50 of posaconazole
was also observed with two double substitutions, Y132FF145L (2.2-fold) and
D278NG464S (4.8-fold), in contrast to the ﬁndings for itraconazole, where no in-
creases in IC50 were observed for the double substitution proteins.
The IC50 studies also revealed that some amino acid substitutions resulted in
residual sterol demethylase activity (3%) at high concentration of an azole (4 M),
which may result in azole tolerance. This residual activity was observed for all of the
enzymes with double substitutions with ﬂuconazole and several other mutation/azole
combinations, which also exhibited greater than 2-fold changes in the IC50. Importantly,
residual activity was also observed for 8 single substitutions (Y132F, F145L, Y257H,
Y447H, V456I, G464S, R467K, and I471T) with ﬂuconazole and 3 single substitutions
(F449Y, R467K, and Q474K) with posaconazole, which did not have greater than 2-fold
changes in the IC50. In these cases, although the IC50 value did not signiﬁcantly
increase, the residual CYP51 activity might favor the survival of the C. albicans strain
with a substitution during a period of azole stress over the survival of the wild-type
strain. In addition, the high level of residual activity in the double mutants, particularly
with ﬂuconazole (Table 3), further highlights the impact of a double mutation on azole
resistance.
Direct azole ligand binding studies using pure recombinant CaCYP51 proteins did
not always reﬂect the observed azole tolerance conferred by an amino acid substitution
on CYP51 enzyme activity. The Kd values for ﬂuconazole for the Y132FK143R and
Y132HK143R enzymes were 312- and 362-fold larger than the value for the wild-type
enzyme, reﬂecting the large increases in observed IC50 values. However, the apparent
Kd values for ﬂuconazole for the D278NG464S enzyme was 3-fold lower than that for
the wild-type enzyme, and the Kd values obtained with the G307SG450E and
Y132FF145L enzymes were only 3- and 4-fold higher than the value for the wild-type
enzyme. Similarly, only the Y132FK143R and Y132HK143R enzymes had substan-
tially larger Kd values (2,300 and 8,000 nM, respectively) for voriconazole than the other
CaCYP51 proteins (3 to 100 nM), while ligand binding experiments with itraconazole
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and posaconazole failed to identify any large changes in apparent Kd values among the
CaCYP51 proteins in this study.
Therefore, azole ligand binding studies in the absence of a substrate and a redox
partner do not always identify the subtle differences between the mutant CaCYP51
proteins. While this may in part be due to the puriﬁed CaCYP51 protein adopting a
conformation in free solution slightly different from that when it is partitioned into a
lipid bilayer in combination with a substrate and a redox partner, it is also consistent
with reports suggesting that substitutions, like G450E, that lie outside of the azole
contact areas of the CYP51 molecule may contribute to azole resistance by other
means, such as inﬂuencing an interaction with cytochrome P450 reductase (CPR) (39).
Azole ligand binding studies are a useful tool to quickly screen new azole compounds
for tight binding against a given CYP51 enzyme; however, effectiveness as a CYP51
inhibitor needs to be conﬁrmed by IC50 studies.
Studies in C. albicans showed that those CYP51 mutants tested had the greatest
effect on resistance to ﬂuconazole (Table 4). This was expected, as most of the
mutations are likely to have arisen in the clinic as a result of prolonged exposure to
ﬂuconazole. The high azole resistance observed with some substitutions correlated well
with large changes in the IC50 and residual activity. All substitutions except D278N
resulted in an increase in the MIC of ﬂuconazole when tested in C. albicans, and
all substitutions except Y132H and D278N resulted in the strain becoming either
susceptible-dose dependent (MIC, 4 g ml1) or resistant (MIC, 8 g ml1) to ﬂu-
conazole, according to CLSI clinical breakpoints, which are used in predicting the
patient response to drug treatment (40). In particular, both the strain with the enzyme
with the double substitution Y132FK143R and the strain with the enzyme with the
double substitution Y132FF145L showed ﬂuconazole MIC changes of 32-fold, in
accordance with their high IC50s and residual activities. Strains with enzymes with
D278NG464S, Y132FK143R, and Y132FF145L showed voriconazole MIC changes
of 8-, 32-, and 32-fold, respectively, compared with that for the susceptible SC5314
isolate, which correlates with their high residual CYP51 activities.
Posaconazole was an effective inhibitor of all the C. albicans strains tested, despite
the fact that most of the CaCYP51 amino acid substitutions gave increased IC50s and
relatively high residual demethylation activity. This is in agreement with the ﬁndings of
previous studies where multiple CaCYP51 amino acid substitutions tested in Saccha-
romyces cerevisiae (including S405F, Y132H, and G464S) did not affect posaconazole
MICs (41). It was also shown that in C. albicans clinical matched isolates, CYP51
substitutions also had a minimal impact on posaconazole susceptibility, except for the
strain with the combination of Y132H and G464S mutations (41). Importantly, this
means that posaconazole remains an effective agent against the ﬂuconazole-resistant
CaCYP51 strains tested here.
None of the mutant CaCYP51 proteins yielded an IC50 value for itraconazole that was
greater than 1.6-fold that for the wild-type CaCYP51 enzyme, although the itraconazole
MIC for the C. albicans mutant strain with the K143R CYP51 substitution was increased
above the susceptible dose-dependent CLSI breakpoint of 0.25 g ml1, which corre-
lates with the 6.3% residual CYP51 activity observed with the recombinant CaCYP51
protein with K143R at 4 M itraconazole. All other tested C. albicans strains (those
with the Y132F, Y132H, F145L, D278N, S405F, G448E, G450E, G464S, Y132FK143R,
Y132FF145L, and D278NG464S substitutions) caused small, albeit consistent, in-
creases in the itraconazole MIC over that for strain SC5314. However, these results do
not support the previous observations that some amino acid substitutions, including
P230L, Y447H, and G450E, conferred itraconazole resistance in clinical C. albicans strains
(23). In these cases, there may have been other resistance mechanisms involved.
In some cases, there was little correlation between the IC50 and the MIC observed.
The individual Y132H, F145L, and G464S substitutions conferred approximately 2-, 4-,
and 5-fold increases in the MIC of ﬂuconazole, respectively, for the mutant strains over
that for SC5314, despite the IC50 for the Y132H protein being less than that for the
wild-type CYP51 and the F145L and G464S substitutions conferring only slightly
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increased catalytic tolerance to ﬂuconazole. The apparent ineffectiveness of several
point mutations that have previously been associated with ﬂuconazole resistance
(especially Y132H, which was one of the ﬁrst substitutions identiﬁed in resistant strains;
F145L; and G464S) was surprising. However, Kudo et al. (26) and Bellamine et al. (27)
established, using in vitro IC50 studies, that F145L contributed the majority of the
increase in azole tolerance observed in the mutant with the double substitution
Y132HF145L.
Similarly, the Y132F, K143R, F145L, and G450E CYP51 mutants showed a 16-fold
increase in voriconazole MIC over that for susceptible isolate SC5314, and the Y132H,
S405F, G448E, and G464S CYP51 mutants also showed 8-fold increases in the MIC for
voriconazole, despite less than 3-fold increases in the IC50 for voriconazole being
observed with the CaCYP51 enzymes with single substitutions.
These ﬁndings for the C. albicans strains suggest that these mutations may reduce
susceptibility by means not detected in our CYP51 reconstitution assays. Therefore, it
can be difﬁcult to demonstrate a direct correlation between the observed phenotype
(azole resistance) of a C. albicans strain and a direct causal effect of a single amino acid
substitution in the CaCYP51 enzyme using the biochemical tools used in the present
study. It is plausible that single substitutions which do not confer remarkably high
residual activities, IC50 values, or relative velocities (such as Y132H, P230L, G307S, and
F449Y) may affect cell tolerance to azoles in ways not measured here.
In summary, the greatest variation in azole susceptibility among the proteins with
CaCYP51 amino acid substitutions was observed for ﬂuconazole, with the mutants with
double substitutions being particularly resistant to inhibition by ﬂuconazole. This
conﬁrms the ﬁnding that the cumulative inhibitory effect of additional substitutions in
CaCYP51 is greater than the effect of individual mutations in isolation and accounts for
the common occurrence of multiple amino acid substitutions in the CYP51 genes
isolated from azole-resistant C. albicans strains. The lesser effects against itraconazole
and posaconazole observed support the suggestion that these agents are plausible
alternative therapies against CYP51-mediated ﬂuconazole-resistant C. albicans. This
observation is consistent with both the C. albicans and Saccharomyces cerevisiae CYP51
structures (39, 42), which predict that longer drug molecules generally correlate with a
greater potency for inhibition of fungal CYP51s. These crystal models show the longer
posaconazole and itraconazole molecules forming additional contacts with the amino
acids that line the substrate access channel, so stabilizing the closed (drug-bound)
conformation of the protein, whereas the smaller ﬂuconazole and voriconazole mole-
cules interact only with the exposed amino acids in the active-site pocket and the
heme. Even so, the possibility that prolonged exposure to other azole agents might
select for additional azole-speciﬁc CYP51 gene mutations in C. albicans must be
considered. In agriculture, complex genotypes with multiple substitutions have been
selected during the changing regimes of azole fungicides deployed over recent de-
cades, and in some countries, wild-type alleles of CYP51 are not seen (43). Nevertheless,
fungal phytopathogens have been managed, and we can hope for similar responses to
the changing genotypes of CYP51 in Candida albicans.
MATERIALS AND METHODS
Construction of C. albicans CYP51 mutant strains. The strains used in this study are shown in Table
5. Strains expressing seven single mutations (Y132F, K143R, F145L, S405F, G448E, G450E, G464S) and
three double mutations (Y132FK143R, Y132FF145L, D278NG464S) were selected from a previous
study (36). Two additional strains expressing the Y132H and D278N CYP51 gene mutations were created
utilizing the SAT1/FLP cassette described previously (44). Brieﬂy, C. albicans isolate SC5314 was trans-
formed via electroporation with inserts of a pSFS2-derived plasmid possessing the SAT1 nourseothricin
resistance marker, FLP recombinase, and mutant CaCYP51 genes of interest. The 5= end of the DNA
fragment contained either the Y132H or D278N CYP51 open reading frame (ORF), and the 3= end
possessed homology downstream of the CaCYP51 stop codon to ensure homologous recombination at
the CYP51 gene locus. Successful transformants were screened on yeast-peptone-dextrose agar plates
containing nourseothricin and conﬁrmed via Southern hybridization. Genomic DNA from nourseothricin-
screened transformants was digested with the HindIII restriction enzyme, and the resulting DNA digests
were loaded on 1% agarose gels containing ethidium bromide. Digested samples were visualized brieﬂy
under UV light after approximately 2 h of electrophoresis (120 V) to conﬁrm appropriate band separation.
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Lanes containing digested DNA in the gel were transferred onto a nitrocellulose membrane via vacuum
suction, and DNA was cross-linked to the membrane through UV exposure. PCR ampliﬁcation of the
genomic DNA from parent isolate SC5314 using primers ERG11_Probe_F (5=-AGTTCAATGGTGGTTTTAC
CTACT-3=) and ERG11_Probe_R (5=-ATTTCTGATTGAGTCATCCTAACA-3=) generated a 254-bp product,
used as a probe for the ERG11 gene locus. The probe was labeled and prepared using an Amersham
AlkPhos direct labeling and detection system (GE Life Sciences) and hybridized to the membrane through
overnight incubation at 55°C. Bands containing the hybridized, alkaline phosphatase-labeled probe
corresponding to either wild-type ERG11 alleles (2,678 bp) or successfully replaced alleles with the
SAT1/FLP cassette included (4,318 bp) or recycled (3,119 bp) were visualized with the CDP-Star chemi-
luminescent detection reagent. To conﬁrm the sequence of the replaced ERG11 allele, a DNA fragment
containing the ERG11 ORF and approximately 435 bp upstream of the start codon and 229 bp down-
stream of the ERG11 stop codon was PCR ampliﬁed using primers CaERG11_A_(ApaI) (5=-GGGCCCG
GGTTATTTGAGAACAGCC-3=) and CaERG11_E_(XhoI) (5=-CTCGAGCCAGTGGACAAAAACCATCA-3=).
The resulting DNA fragment was puriﬁed and Sanger sequenced on an ABI model 3130XL genetic
analyzer with the following sequencing primers: CaERG11SeqA (5=-GCCACCACACCCTATGGCTATT-
3=), CaERG11SeqB (5=-TATTTTCACTGCTTCAAGATCT-3=), CaERG11SeqC (5=-CCAAAAGGTCATTATGTTT
TAG-3=), CaERG11SeqD (5=-CATACAAGTTTCTCTTTTTTCC-3=), CaERG11SeqE (5=-CATTTAGGTGAAAAAC
CTCATT-3=), and CaERG11SeqF (5=-TACTCCAGTTTTCGGTAAAGGG-3=).
Susceptibility testing of C. albicans CYP51 mutant strains. Azole MICs were determined using the
broth microdilution method described by the Clinical Laboratory and Standards Institute (45, 46). Cells
were incubated in 96-well microtiter plates containing RPMI 1640 medium and serially diluted concen-
trations of either ﬂuconazole, itraconazole, voriconazole, or posaconazole. The concentrations for MIC
determinations ranged from 0.125 to 64 g ml1 for ﬂuconazole and 0.03 to 16 g ml1 for itraconazole,
voriconazole, and posaconazole. Measurements were read visually at 24 h after incubation at 35°C for a
50% reduction in growth from that in the drug-free control wells. MIC measurements were performed in
duplicate, and the MIC was reported as the higher of two values for all strains tested. In cases where the
duplicate MIC values were not identical, the higher of the two MIC values is reported. Overall, the MIC
values were consistent with 92% (184/200) of the MICs being within a single dilution of each other for
a given strain and drug combination. Additionally, no MICs differed by more than 2 dilutions for a given
strain and drug.
Construction of pCWori:CaCYP51 expression vectors for expression in E. coli. Wild-type C.
albicans CYP51 (UniProtKB accession number P10613) and 28 mutant C. albicans CYP51 genes, 23 coding
for single amino acid substitutions and 5 coding for double substitutions, were synthesized by Euroﬁns-
MWG-Operon (Ebersberg, Germany) and inserted into a shuttle vector with kanamycin selection using
NdeI and HindIII cloning sites ﬂanking the start and stop codons, respectively. All the CaCYP51 genes
were modiﬁed so that the ﬁrst 8 amino acids encoded MALLLAVF to facilitate expression in E. coli (47),
and a 12-base sequence (CATCACCATCAC) encoding a 4-histidine tag was inserted immediately in front
of the stop codon to facilitate protein puriﬁcation by Ni2-NTA agarose afﬁnity chromatography. All 29
genes were codon optimized for expression in E. coli.
The CaCYP51 genes were excised by digestion with NdeI and HindIII, gel puriﬁed, and then ligated
into the pCWori expression vector that had previously been cut with NdeI and HindIII. Positive
recombinants were isolated by transformation into E. coli strain DH5 and selected on LB agar plates
containing 0.1 mg ml1 sodium ampicillin. The sequence integrity of each pCWori:CaCYP51 construct
was checked by DNA sequencing in both directions (Euroﬁns-MWG-Operon) at this stage and then again
from a plasmid preparation derived from the overnight cultures used to inoculate the protein expression
culture ﬂasks.
The CaCYP51 single amino acid substitutions synthesized were Y118A, F126V, Y132F, Y132H, K143R,
F145L, P230L, Y257H, D279N, S279F, G307S, S405F, V437I, Y447H, G448E, F449Y, G450E, V456I, G464S,
TABLE 5 Strains used in this study
Strain Genotype Source or reference
SC5314 ERG11-1/ERG11-2 ATCC
Constructed laboratory strainsa
20E1II1G1 ERG11Y132F::FRT/ERG11Y132F::FRTb 36
SCERG11R1S1C1 ERG11Y132H::FRT/ERG11Y132H::FRT This study
10B1A32A ERG11K143R::FRT/ERG11K143R::FRT 36
2A1A18A ERG11F145L::FRT/ERG11F145L::FRT 36
SCERG11R3S3C1 ERG11D278N::FRT/ERG11D278N::FRT This study
21C1M1A1 ERG11S405F::FRT/ERG11S405F::FRT 36
20NA11A57A ERG11G448E::FRT/ERG11G448E::FRT 36
15A3A108A ERG11G450E::FRT/ERG11G450E::FRT 36
19A1A1C1 ERG11G464S::FRT/ERG11G464S::FRT 36
9A14A21 ERG11Y132F,K143R::FRT/ERG11Y132F,K143R::FRT 36
27A5A33A ERG11Y132F,F145L::FRT/ERG11Y132F,F145L::FRT 36
13A1A57A ERG11D278N,G464S::FRT/ERG11D278N,G464S::FRT 36
aAll laboratory strains have SC5314 as the background.
bFRT, FLP recombination target.
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R467K, I471T, Q474K, and V488I, and the double substitutions were Y132FK143R, Y132HK143R,
Y132FF145L, D278NG464S, and G307SG450E.
Heterologous expression in E. coli and isolation of recombinant CaCYP51 proteins. The
pCWori:CaCYP51 constructs were transformed into competent E. coli DH5 cells, and transformants
were selected using 0.1 mg ml1 sodium ampicillin. One-liter volumes of Terriﬁc broth (1.2% tryptone,
2.4% yeast extract, 0.4% glycerol, 0.09 M potassium phosphate, pH 7.5) containing 0.1 mg ml1 sodium
ampicillin in 2-liter plastic bafﬂed ﬂasks were inoculated with 20 ml of an overnight culture of the
expression clones. The cultures were shaken at 200 rpm and 37°C for 7 h, followed by induction with
1 mM isopropyl -D-1-thiogalactopyranoside and 1 mM the heme precursor 5-aminolevulinic acid, prior
to shaking for a further 16 h at 160 rpm and 27°C. Protein isolation was done according to the method
of Arase et al. (48), except that 2% sodium cholate was used in the sonication buffer. The solubilized
CYP51 proteins were puriﬁed by afﬁnity chromatography using Ni2-NTA agarose as previously de-
scribed (30), with the modiﬁcation that 0.1% L-histidine in 0.1 M Tris-HCl (pH 8.1) and 25% glycerol were
used to elute nonspeciﬁcally bound E. coli proteins after the salt washes. The CaCYP51 proteins were
recovered by elution with 1% L-histidine in 0.1 M Tris-HCl (pH 8.1) and 25% glycerol, followed by dialysis
against 5 liters of 25 mM Tris-HCl (pH 8.1) and 10% glycerol. The Ni2-NTA agarose-puriﬁed CaCYP51
proteins were used for all subsequent spectral and IC50 determinations. Protein purity was assessed by
SDS-polyacrylamide gel electrophoresis.
Determination of cytochrome P450 protein concentrations. Reduced carbon monoxide differ-
ence spectra (49) were used to determine the cytochrome P450 concentration, with carbon monoxide
being passed through the cytochrome P450 solution prior to addition of sodium dithionite to the sample
cuvette. An extinction coefﬁcient of 91 mM1 · cm1 (50) was used to calculate the cytochrome P450
concentrations from the absorbance difference between 445 to 447 nm and 490 nm. Absolute spectra at
wavelengths between 700 and 300 nm were determined using 20-fold dilutions of the puriﬁed CaCYP51
proteins in 0.1 M Tris-HCl (pH 8.1) and 20% glycerol as previously described (30). Conﬁrmation that the
isolated CaCYP51 proteins were active was demonstrated by measuring the 14-demethylation of
lanosterol using the CYP51 reconstitution assay detailed below.
CYP51 reconstitution assay system. IC50 determinations were performed using the CYP51 recon-
stitution assay system (ﬁnal reaction volume, 500 l) previously described (51) containing 1 M CaCYP51,
2 M Homo sapiens cytochrome P450 reductase (UniProtKB accession number P16435), 50 M lanosterol,
50 M sn-dilaurylphosphatidylcholine, 4% (wt/vol) 2-hydroxypropyl--cyclodextrin, 0.4 mg ml1 isoci-
trate dehydrogenase, 25 mM trisodium isocitrate, 50 mM NaCl, 5 mM MgCl2, and 40 mM MOPS (mor-
pholinepropanesulfonic acid; pH 7.2). Azole antifungal agents were added in 2.5 l dimethyl sulfoxide,
followed by 10 min of incubation at 37°C prior to assay initiation with 4 mM -NADPH-Na4. The samples
were then shaken for 15 min at 37°C. Sterol metabolites were recovered by extraction with ethyl acetate,
followed by derivatization with 0.1 ml N,O-bis(trimethylsilyl)triﬂuoroacetamide (BSTFA)–trimethylchlo-
rosilane (TMCS) (99:1) and 0.3 ml anhydrous pyridine (2 h at 80°C), prior to analysis by gas
chromatography-mass spectrometry (GC-MS) (52). IC50 determinations were performed in duplicate.
Azole binding studies. Studies of azole antifungal binding to 4 M CaCYP51 proteins were per-
formed as previously described (53) using quartz split cuvettes with a 4.5-mm light path. Stock 1-, 0.5-,
0.2-, and 0.1-mg ml1 solutions of ﬂuconazole, itraconazole, voriconazole, and posaconazole were
prepared in dimethyl sulfoxide. Azole antifungals were progressively titrated against the CaCYP51
proteins in 0.1 M Tris-HCl (pH 8.1) and 25% glycerol at 22°C, with equivalent volumes of dimethyl
sulfoxide also being added to the CYP51-containing compartment of the reference cuvette. The
absorbance difference spectra between 500 and 350 nm were determined after each incremental
addition of azole, with binding saturation curves constructed from the change in the peak and trough
absorbance (ΔApeak-trough) against the azole concentration. The dissociation constant (Kd) of the enzyme-
azole complex for each azole was determined by nonlinear regression (Levenberg-Marquardt algorithm)
using a rearrangement of the Morrison equation for tight ligand binding (54, 55). Tight binding is
normally observed when the Kd for a ligand is similar to or lower than the concentration of the enzyme
present (56). Where ligand binding was weak, the Michaelis-Menten equation was used to ﬁt the data.
Each binding determination was performed in triplicate. The chemical structures of the azole antifungals
used in this study are shown in Fig. S5 in the supplemental material.
Data analysis. Curve ﬁtting of the ligand binding data was performed using the computer program
ProFit (version 6.1.12; QuantumSoft, Zurich, Switzerland). Spectral determinations were made using
quartz semimicrocuvettes with a Hitachi U-3310 UV/visible spectrophotometer (San Jose, CA).
Chemicals. All chemicals, including all azole antifungals except voriconazole, were obtained from
Sigma Chemical Company (Poole, UK). Voriconazole was supplied by Discovery Fine Chemicals (Bour-
nemouth, UK). Growth media, sodium ampicillin, IPTG, and 5-aminolevulenic acid were obtained from
Foremedium Ltd. (Hunstanton, UK). The Ni2-NTA agarose afﬁnity chromatography matrix was obtained
from Qiagen (Crawley, UK).
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